• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Speculation is not evidence: antihypertensive therapy and COVID-19.推测并非证据：抗高血压治疗与新型冠状病毒肺炎
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):133-134. doi: 10.1093/ehjcvp/pvaa021.
2
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新冠病毒病风险？
Lancet Respir Med. 2020 May;8(5):e30-e31. doi: 10.1016/S2213-2600(20)30153-3. Epub 2020 Mar 26.
3
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新型冠状病毒肺炎风险？
Lancet Respir Med. 2020 May;8(5):e29. doi: 10.1016/S2213-2600(20)30156-9. Epub 2020 Mar 26.
4
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新型冠状病毒肺炎风险？
Lancet Respir Med. 2020 May;8(5):e28. doi: 10.1016/S2213-2600(20)30158-2. Epub 2020 Mar 26.
5
Antihypertensive drugs and risk of COVID-19? - Authors' reply.抗高血压药物与2019冠状病毒病风险？——作者回复
Lancet Respir Med. 2020 May;8(5):e32-e33. doi: 10.1016/S2213-2600(20)30159-4. Epub 2020 Mar 26.
6
Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence.在新冠疫情期间更换抗高血压治疗方案：为何我们应等待证据。
Eur Heart J. 2020 May 14;41(19):1857. doi: 10.1093/eurheartj/ehaa335.
7
Could patients taking isotretinoin therapy be immune against SARS-CoV-2?正在接受异维甲酸治疗的患者对SARS-CoV-2有免疫力吗？
Dermatol Ther. 2020 Jul;33(4):e13573. doi: 10.1111/dth.13573. Epub 2020 May 29.
8
Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension.对合并高血压的新型冠状病毒肺炎患者使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂进行降压治疗。
Hypertens Res. 2020 Jun;43(6):588-590. doi: 10.1038/s41440-020-0433-1. Epub 2020 Mar 30.
9
Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis.年龄而非性别可能解释动脉高血压和糖尿病对新冠病毒疾病预后的负面影响。
J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.05.010. Epub 2020 May 11.
10
Angiotensin receptor blockers and COVID-19.血管紧张素受体阻滞剂与 COVID-19。
Pharmacol Res. 2020 Jun;156:104832. doi: 10.1016/j.phrs.2020.104832. Epub 2020 Apr 15.

引用本文的文献

1
Brief review: Cardiac complications and platelet activation in COVID-19 infection.简要综述：新型冠状病毒肺炎感染中的心脏并发症与血小板活化
Afr J Thorac Crit Care Med. 2020 Sep 16;26(3). doi: 10.7196/AJTCCM.2020.v26i3.107. eCollection 2020.
2
Cardiac complications in community-acquired pneumonia and COVID-19.社区获得性肺炎和新型冠状病毒肺炎的心脏并发症
Afr J Thorac Crit Care Med. 2020 May 14;26(2). doi: 10.7196/AJTCCM.2020.v26i2.077. eCollection 2020.
3
Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis.肾素-血管紧张素-醛固酮系统阻滞剂使用与冠状病毒病患者急性肾损伤风险增加：系统评价和荟萃分析。
Sci Rep. 2021 Jun 30;11(1):13588. doi: 10.1038/s41598-021-92323-8.
4
Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.肾素-血管紧张素系统抑制与 COVID-19 感染和死亡风险：系统评价和荟萃分析。
Intern Med J. 2020 Dec;50(12):1468-1474. doi: 10.1111/imj.15002. Epub 2020 Nov 16.
5
Risk factors associated with disease aggravation among 126 hospitalized patients with COVID-19 in different places in China: A retrospective observational study.中国不同地区126例住院COVID-19患者疾病加重的相关危险因素：一项回顾性观察研究。
Medicine (Baltimore). 2020 Nov 6;99(45):e22971. doi: 10.1097/MD.0000000000022971.
6
SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease.SARS-CoV-2 受体网络在糖尿病和 COVID-19 相关肾脏疾病中的作用。
Kidney Int. 2020 Dec;98(6):1502-1518. doi: 10.1016/j.kint.2020.09.015. Epub 2020 Oct 8.
7
Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?2019 年冠状病毒病是否会引起特定的心血管损伤，还是会使已存在的心血管疾病恶化？
Pathol Res Pract. 2020 Sep;216(9):153086. doi: 10.1016/j.prp.2020.153086. Epub 2020 Jun 26.
8
Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system - An overlooked association?2019冠状病毒病（Covid-19）患者中结缔组织病的报告率极低与肾素-血管紧张素系统——一种被忽视的关联？
Eur J Intern Med. 2020 Oct;80:106-107. doi: 10.1016/j.ejim.2020.06.012. Epub 2020 Jun 12.
9
Related molecular mechanisms of COVID-19, hypertension, and diabetes.新型冠状病毒肺炎、高血压和糖尿病的相关分子机制
Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E881. doi: 10.1152/ajpendo.00164.2020.
10
Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.高血压、血栓形成、肾衰竭与糖尿病：新型冠状病毒肺炎是一种内皮疾病吗？临床及基础证据的综合评估
J Clin Med. 2020 May 11;9(5):1417. doi: 10.3390/jcm9051417.

本文引用的文献

1
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
2
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
3
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
4
Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.肾素-血管紧张素系统阻断剂停药与估算肾小球滤过率低的患者全因死亡率的关系。
JAMA Intern Med. 2020 May 1;180(5):718-726. doi: 10.1001/jamainternmed.2020.0193.
5
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2（ACE2）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体：分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
6
Structure analysis of the receptor binding of 2019-nCoV.2019新型冠状病毒受体结合的结构分析
Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40. doi: 10.1016/j.bbrc.2020.02.071.
7
Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.应对宿主对新发病毒疾病的反应：从脓毒症、肺炎、流感和埃博拉疫情中汲取的经验教训。
Ann Transl Med. 2016 Nov;4(21):421. doi: 10.21037/atm.2016.11.03.
8
Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers.治疗埃博拉患者：使用普通他汀类药物和血管紧张素受体阻滞剂的“自下而上”方法。
Int J Infect Dis. 2015 Jul;36:80-4. doi: 10.1016/j.ijid.2015.04.019.
9
Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study.在曼哈顿北部研究中高血压和糖尿病对心血管疾病及中风的人群归因风险
J Am Heart Assoc. 2014 Sep 16;3(5):e001106. doi: 10.1161/JAHA.114.001106.
10
Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis.血管紧张素-（1-9）通过抑制血管紧张素转换酶/血管紧张素II轴来逆转实验性高血压和心血管损伤。
J Hypertens. 2014 Apr;32(4):771-83. doi: 10.1097/HJH.0000000000000094.

Speculation is not evidence: antihypertensive therapy and COVID-19.

作者信息

de Simone Giovanni, Mancusi Costantino

机构信息

Hypertension Research Center, Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):133-134. doi: 10.1093/ehjcvp/pvaa021.

DOI:10.1093/ehjcvp/pvaa021
PMID:32236478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7184342/
Abstract
摘要